Form 4: Ionis Pharmaceuticals EVP Richard S. Geary Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Richard S. Geary, EVP and Chief Development Officer of Ionis Pharmaceuticals, sold 2,430 shares of common stock at $48 per share on August 5, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On August 5, 2024, Richard S. Geary, the Executive Vice President and Chief Development Officer of Ionis Pharmaceuticals, sold 2,430 shares of the company's common stock.
- The shares were sold at a price of $48 per share.
- The transaction was executed under a Rule 10b5-1 trading plan that Geary adopted on April 8, 2024.
- Following the transaction, Geary directly owns 85,508 shares of Ionis Pharmaceuticals.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
Sales by executives are a normal part of executive compensation. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 04/08/2024 | Date the reporting person adopted the Rule 10b5-1 Trading Plan |
| 08/05/2024 | Date of the transaction (stock sale) |
| 08/06/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.